Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023.

Gynecol Oncol Rep · 2026 · PMC13253191 · PMID 42294114

Europe PMC DOI

hedged sentence

0.8900

closest p · 17.8× alpha

0.8900

boldest claim

The sentences

a nonsignificant trendp = 0.89not close (p > 0.1)

At the same time, we observed that the annual ratio of 0.08 fatal anaphylaxis associated with carboplatin reported for every anaphylaxis report was flat, with a nonsignificant trend (p = 0.89).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.